Complix, a biopharmaceutical company developing a pipeline of transformative Cell Penetrating Alphabod (CPABs) announced that its Chief Scientific Officer, Dr Yvonne McGrath, will be presenting its recent developments on CPABs against intracellular targets at the 9th Annual PEGS (Protein and Antibody Engineering Summit) Europe Meeting in Lisbon Portugal on November 13-17.

In her presentation Dr McGrath will give insight into Complix’ recent progress with respect to CAPBs acting on important intracellular cancer targets.

There will be a detailed talk on “Alphabodies: A Novel Class of Biologicals Acting on Intracellular Targets”;  “Engineering Antibodies: Novel Antibodies and Antibody Subtypes as Therapeutics.”.

Complix is a biopharmaceutical company developing a pipeline of transformative Cell Penetrating Alphabodie (CPABs) based therapeutics against a number of cutting-edge and challenging intracellular targets playing an important role in oncology. These CPABs act with great precision and high affinity on targets that are considered “intractable” by current drug formats, such as antibodies or small chemicals. Complix has an ongoing strategic collaboration with Merck & Co to develop novel CPAB based therapeutics against two selected intracellular cancer targets. Under the terms of this collaboration, which was recently expanded, Complix is eligible to receive up to $280 million in upfront and development and regulatory milestones as well as tiered mid-single digit royalties on global sales revenues.